GC
BLPH

Grace Capital’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Grace Capital’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-306
Closed -$11K – 229
2018
Q2 		$11K Buy
+306
New +$10.6K ﹤0.01% 217

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Grace Capital's BLPH Position: Q3 2018 in Review

Grace Capital sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2018, closing a stake of 306 shares — an estimated $11K sold.

Grace Capital first reported a position in BLPH in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 30 funds tracked by Wall St. Rank hold BLPH as of Q3 2018.

  • Grace Capital reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Grace Capital sold 306 Bellerophon Therapeutics, Inc. shares in Q3 2018, an estimated $11K.
  • Grace Capital first reported a position in Bellerophon Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Grace Capital's Bellerophon Therapeutics, Inc. position peaked at $11K in Q2 2018.
  • 30 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2018.

Based on Grace Capital's 13F filing for Q3 2018, filed 14 Nov 2018.